The widespread belief that creatine offers anti-inflammatory benefits beyond its established muscle-building effects appears unfounded, according to the most comprehensive analysis to date of this popular supplement's impact on immune markers. This finding matters for the millions of health-conscious adults who take creatine not just for fitness gains but hoping for broader longevity benefits through reduced inflammation.
Researchers analyzed eight randomized controlled trials examining creatine's effects on key inflammatory biomarkers including C-reactive protein, interleukin-6, and tumor necrosis factor-alpha. The pooled data revealed no statistically significant reductions in any inflammatory marker, whether measured acutely after supplementation or following chronic use. Effect sizes were minimal across all outcomes, with confidence intervals consistently crossing zero, indicating no meaningful biological impact on systemic inflammation.
This meta-analysis provides important clarity in a field where individual studies have produced conflicting results. While creatine remains one of the most evidence-backed supplements for muscle strength and power output, these findings suggest its therapeutic value may be more limited than recent marketing claims suggest. The moderate-quality evidence included diverse populations from healthy athletes to clinical groups, strengthening the generalizability of these null findings. For longevity-focused individuals, this research underscores the importance of evidence-based supplement choices rather than relying on theoretical mechanisms or preliminary studies. The results don't diminish creatine's established benefits for muscle function and cognitive performance, but they do temper expectations about its role as an anti-aging compound through inflammatory pathways.